Cited by 1,357RNA Interference and Gene DeliveryVirus-based gene therapy researchRNA Research and Splicing

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

RNAi-mediated gene silencing in non-human primates

Zimmermann, Tracy S., Lee, Amy C. H., Akinc, Akin, Bramlage, Birgit, Bumcrot, David, Fedoruk, Matthew N., Harborth, Jens, Heyes, James A., Jeffs, Lloyd B., John, Matthias, Judge, Adam D., Lam, Kieu, McClintock, Kevin, Nechev, Lubomir V., Palmer, Lorne R., Racie, Timothy, Röhl, Ingo, Seiffert, Stephan, Shanmugam, Sumi, Sood, Vandana, Soutschek, Jürgen, Toudjarska, Ivanka, Wheat, Amanda J., Yaworski, Ed, Zedalis, William, Koteliansky, Victor, Manoharan, Muthiah, Vornlocher, Hans-Peter, MacLachlan, Ian·2006·Nature

DOI 10.1038/nature04688

Open this paper in CoChat — free account

Abstract

The opportunity to harness the RNA interference (RNAi) pathway to silence disease-causing genes holds great promise for the development of therapeutics directed against targets that are otherwise not addressable with current medicines. Although there are numerous examples of in vivo silencing of target genes after local delivery of small interfering RNAs (siRNAs), there remain only a few reports of RNAi-mediated silencing in response to systemic delivery of siRNA, and there are no reports of systemic efficacy in non-rodent species. Here we show that siRNAs, when delivered systemically in a liposomal formulation, can silence the disease target apolipoprotein B (ApoB) in non-human primates. APOB-specific siRNAs were encapsulated in stable nucleic acid lipid particles (SNALP) and administered by intravenous injection to cynomolgus monkeys at doses of 1 or 2.5 mg kg(-1). A single siRNA injection resulted in dose-dependent silencing of APOB messenger RNA expression in the liver 48 h after administration, with maximal silencing of >90%. This silencing effect occurred as a result of APOB mRNA cleavage at precisely the site predicted for the RNAi mechanism. Significant reductions in ApoB protein, serum cholesterol and low-density lipoprotein levels were observed as early as 24 h after treatment and lasted for 11 days at the highest siRNA dose, thus demonstrating an immediate, potent and lasting biological effect of siRNA treatment. Our findings show clinically relevant RNAi-mediated gene silencing in non-human primates, supporting RNAi therapeutics as a potential new class of drugs.

Integrity signals

Registry

Crossref · 10.1038/nature04688

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A Receptor-Mediated Pathway for Cholesterol Homeostasis
Brown, M. S., & Goldstein, J. L. (1986) · Science · doi:10.1126/science.3513311 · Cited by 5,703
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
C-Reactive Protein Levels and Outcomes after Statin Therapy
Ridker, P. M., Cannon, C. P., Morrow, D., Rifai, N., Rose, L. M., McCabe, C. H., Pfeffer, M. A., & Braunwald, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042378 · Cited by 2,292
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
Soutschek, J., Akinc, A., Bramlage, B., Charissé, K., Constien, R., Donoghue, M., Elbashir, S. M., Geick, A., Hadwiger, P., Harborth, J., et al. (2004) · Nature · doi:10.1038/nature03121 · Cited by 2,206
Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7
Hornung, V., Guenthner‐Biller, M., Bourquin, C., Ablasser, A., Schlee, M., Uematsu, S., Noronha, A. M., Manoharan, M., Akira, S., de Fougerolles, A., et al. (2005) · Nature Medicine · doi:10.1038/nm1191 · Cited by 1,261
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,260
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs
Morrissey, D. V., Lockridge, J. A., Shaw, L., Blanchard, K. S., Jensen, K., Breen, W., Hartsough, K. C., Machemer, L., Radka, S. F., Jadhav, V., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1122 · Cited by 1,175
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,027
The RNAi revolution
Novina, C. D., & Sharp, P. A. (2004) · Nature · doi:10.1038/430161a · Cited by 739
Inhibition of respiratory viruses by nasally administered siRNA
Bitko, V., Musiyenko, A., Shulyayeva, O., & Barik, S. (2004) · Nature Medicine · doi:10.1038/nm1164 · Cited by 731

Show all 20 references

Sorted by citations

Items 101–200 of 1,001

Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core
Leung, A. K. K., Hafez, I. M., Baoukina, S., Belliveau, N. M., Zhigaltsev, I. V., Afshinmanesh, E., Tieleman, D. P., Hansen, C., Hope, M. J., & Cullis, P. (2012) · The journal of physical chemistry. C, Nanomaterials and interfaces · doi:10.1021/jp303267y · Cited by 339
Biopharmaceutical benchmarks 2006
Walsh, G. (2006) · Nature Biotechnology · doi:10.1038/nbt0706-769 · Cited by 359
Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets
Klingenberg, M., Matsuda, A., Diederichs, S., & Patel, T. C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.04.009 · Cited by 355
“For instance, a 90% knockdown of Apolipoprotein B (APOB) in the liver of Macaca fascicularis was noted 48h after a single intravenous siRNA injection [181].”
Background
Development of Lipidoid–siRNA Formulations for Systemic Delivery to the Liver
Akinc, A., Goldberg, M., Qin, J., Dorkin, J. R., Gamba-Vitalo, C., Maier, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Manoharan, M., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.36 · Cited by 323
A New Potent Secondary Amphipathic Cell–penetrating Peptide for siRNA Delivery Into Mammalian Cells
Crombez, L., Aldrian, G., Konate, K., Nguyen, Q., McMaster, G., Brasseur, R., Heitz, F., & Divita, G. (2008) · Molecular Therapy · doi:10.1038/mt.2008.215 · Cited by 361
siRNA Conjugate Delivery Systems
Jeong, J. H., Mok, H., Oh, Y., & Park, T. G. (2008) · Bioconjugate Chemistry · doi:10.1021/bc800278e · Cited by 345
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., & MacLachlan, I. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37515 · Cited by 337
RNA Interference: From Basic Research to Therapeutic Applications
Kurreck, J. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200802092 · Cited by 347
Nucleic acid delivery for therapeutic applications
Gupta, A., Andresen, J. L., Manan, R. S., & Langer, R. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113834 · Cited by 352
State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery
Evers, M. J. W., Kulkarni, J. A., van der Meel, R., Cullis, P. R., Vader, P., & Schiffelers, R. M. (2018) · Small Methods · doi:10.1002/smtd.201700375 · Cited by 332
Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study
Suhr, O. B., Coelho, T., Buades, J., Pouget, J., Conceicao, I., Berk, J., Schmidt, H., Waddington-Cruz, M., Campistol, J. M., Bettencourt, B. R., et al. (2015) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-015-0326-6 · Cited by 321
“Lipid nanoparticles (LNPs) deliver siRNAs to hepatocytes, resulting in the robust and durable reduction in expression (so-called “knockdown”) of gene targets across multiple species [18–23].”
Background
Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device
Shepherd, S. J., Warzecha, C. C., Yadavali, S., El-Mayta, R. D., Alameh, M., Wang, L., Weissman, D., Wilson, J. M., Issadore, D., & Mitchell, M. J. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c01353 · Cited by 324
Sustained Small Interfering RNA Delivery by Mesoporous Silicon Particles
Tanaka, T., Mangala, L. S., Vivas‐Mejía, P. E., Nieves-Alicea, R., Mann, A. P., Mora, E., Han, H., Shahzad, M. M. K., Liu, X., Bhavane, R. C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3931 · Cited by 317
Efficient In Vivo Delivery of siRNA to the Liver by Conjugation of α-Tocopherol
Nishina, K., Unno, T., Uno, Y., Kubodera, T., Kanouchi, T., Mizusawa, H., & Yokota, T. (2008) · Molecular Therapy · doi:10.1038/mt.2008.14 · Cited by 323
A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo
Sato, Y., Hatakeyama, H., Sakurai, Y., Hyodo, M., Akita, H., & Harashima, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.09.009 · Cited by 310
Efficient and targeted delivery of siRNA in vivo
Shim, M. S., & Kwon, Y. J. (2010) · FEBS Journal · doi:10.1111/j.1742-4658.2010.07904.x · Cited by 320
Biological Barriers to Therapy with Antisense and siRNA Oligonucleotides
Juliano, R. L., Bauman, J. A., Kang, H. M., & Ming, X. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900093r · Cited by 306
Engineering RNA for Targeted siRNA Delivery and Medical Application
Guo, P., Coban, O., Snead, N. M., Trebley, J., Hoeprich, S., Guo, S., & Shu, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.03.008 · Cited by 311
“5 mgkg, resulting in a 65% reduction of serumcholesterol [150].”
Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo
Andaloussi, S. E., Lehto, T., Mäger, I., Rosenthal-Aizman, K., Oprea, I. I., Simonson, O. E., Sork, H., Ezzat, K., Copolovici, D. M., Kurrikoff, K., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1299 · Cited by 310
“The majority of previous other successful RNAi reports are indeed based on results achieved from the liver, whereas efficient gene knockdown in other organs requires much more complicated strategies and multicomponent delivery vectors (29,30).”
Background
IGF1R signalling and its inhibition
Riedemann, J., & Macaulay, V. M. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01280 · Cited by 306
Antisense oligonucleotide pharmacokinetics and metabolism
Geary, R. S. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902877680 · Cited by 303
“(2009) 5(4) approaches for RNAi have shown promising single dose pharmacology in the liver of nonhuman primates [35,36].”
Background
Gold Nanoparticles Capped with Polyethyleneimine for Enhanced siRNA Delivery
Song, W., Du, J., Sun, T., Zhang, P., & Wang, J. (2009) · Small · doi:10.1002/smll.200901513 · Cited by 298
A status report on RNAi therapeutics
Vaishnaw, A. K., Gollob, J., Gamba‐Vitalo, C., Hutabarat, R. M., Sah, D. W. Y., Meyers, R. E., de Fougerolles, T., & Maraganore, J. M. (2010) · Silence · doi:10.1186/1758-907x-1-14 · Cited by 305
“With optimization to further increase the circulation t1/2 relative to LNPs delivering to the liver, LNPmediated extrahepatic delivery to subcutaneous tumors in mice has been achieved [29].”
BackgroundInfluential
RNAi-based drug design: considerations and future directions
Tang, Q., & Khvorova, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00912-9 · Cited by 333
siRNA therapeutics: a clinical reality
Saw, P. E., & Song, E. (2019) · Science China Life Sciences · doi:10.1007/s11427-018-9438-y · Cited by 300
The canonical Wnt signalling pathway and its APC partner in colon cancer development
Schneikert, J., & Behrens, J. (2006) · Gut · doi:10.1136/gut.2006.093310 · Cited by 302
Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development
Drummond, D. C., Noble, C. O., Hayes, M. E., Park, J. W., & Kirpotin, D. B. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21358 · Cited by 292
RNAi therapeutic and its innovative biotechnological evolution
Weng, Y., Xiao, H., Zhang, J., Liang, X., & Huang, Y. (2019) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.04.012 · Cited by 293
Chemical modification: the key to clinical application of RNA interference?
Corey, D. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33483 · Cited by 287
RNAi‐based therapeutics–current status, challenges and prospects
Tiemann, K., & Rossi, J. J. (2009) · EMBO Molecular Medicine · doi:10.1002/emmm.200900023 · Cited by 285
Overcoming the Innate Immune Response to Small Interfering RNA
Judge, A. D., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.179 · Cited by 281
Physicochemical and Biological Characterization of Targeted, Nucleic Acid-Containing Nanoparticles
Bartlett, D. W., & Davis, M. E. (2007) · Bioconjugate Chemistry · doi:10.1021/bc0603539 · Cited by 287
Genomic Screening with RNAi: Results and Challenges
Mohr, S. E., Bakal, C., & Perrimon, N. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060408-092949 · Cited by 293
RNAi Mechanisms and Applications
Kim, D. H., & Rossi, J. J. (2008) · BioTechniques · doi:10.2144/000112792 · Cited by 308
Action and Reaction: The Biological Response to siRNA and Its Delivery Vehicles
Kanasty, R. L., Whitehead, K. A., Vegas, A. J., & Anderson, D. G. (2012) · Molecular Therapy · doi:10.1038/mt.2011.294 · Cited by 290
Gold, Poly(β-amino ester) Nanoparticles for Small Interfering RNA Delivery
Lee, J., Green, J. J., Love, K. T., Sunshine, J. C., Langer, R., & Anderson, D. G. (2009) · Nano Letters · doi:10.1021/nl9009793 · Cited by 276
Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1
Peer, D., Zhu, P., Carman, C. V., Lieberman, J., & Shimaoka, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608491104 · Cited by 276
Designing siRNA That Distinguish between Genes That Differ by a Single Nucleotide
Schwarz, D. S., Ding, H., Kennington, L. A., Moore, J. T., Schelter, J. M., Burchard, J., Linsley, P. S., D, N. A. M., Xu, Z., & Zamore, P. D. (2006) · PLoS Genetics · doi:10.1371/journal.pgen.0020140 · Cited by 274
Advances in siRNA delivery in cancer therapy
Singh, A. P., Trivedi, P., & Jain, N. K. (2017) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2017.1307210 · Cited by 281
“demonstrated the ability of SNALPs to enable knockdown of ApoB in the liver of cynomolgus monkeys [48].”
Background
Design of multifunctional non-viral gene vectors to overcome physiological barriers: Dilemmas and strategies
Wang, T., Upponi, J. R., & Torchilin, V. P. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.013 · Cited by 272
Lipid-based nanoparticle technologies for liver targeting
Böttger, R., Pauli, G., Chao, P., Fayez, N. A., Hohenwarter, L., & Li, S. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.017 · Cited by 276
Gene Silencing by Gold Nanoshell-Mediated Delivery and Laser-Triggered Release of Antisense Oligonucleotide and siRNA
Huschka, R., Barhoumi, A., Liu, Q. L., Roth, J. A., Ji, L., & Halas, N. J. (2012) · ACS Nano · doi:10.1021/nn301135w · Cited by 266
“tumors in animal models, including nonhuman primate.(2,3,6) These RNA or DNA”
Background
Application of the Nano-Drug Delivery System in Treatment of Cardiovascular Diseases
Deng, Y., Zhang, X., Shen, H., He, Q., Wu, Z., Liao, W., & Yuan, M. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00489 · Cited by 263
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy
Gulino, A. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s23696 · Cited by 264
Inhibition of microRNA with antisense oligonucleotides
Esau, C. (2007) · Methods · doi:10.1016/j.ymeth.2007.11.001 · Cited by 260
siRNA nanoparticles targeting CaMKIIγ in lesional macrophages improve atherosclerotic plaque stability in mice
Tao, W., Yurdagul, A., Kong, N., Li, W., Wang, X., Doran, A. C., Feng, C., Wang, J., Islam, M. A., Farokhzad, O. C., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1063 · Cited by 259
Liposomal nanomedicines
Fenske, D. B., & Cullis, P. R. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.1.25 · Cited by 256
MicroRNA-199b-5p Impairs Cancer Stem Cells through Negative Regulation of HES1 in Medulloblastoma
Garzia, L., Andolfo, I., Cusanelli, E., Marino, N., Petrosino, G., Martino, D. D., Esposito, V., Galeone, A., Navas, L., Esposito, S., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004998 · Cited by 254
“These have been demonstrated to be effective in non-human primates for systemic delivery, and would bypassing the blood-brain barrier using encapsulated nano-particles containing agomir 199b-5p molecules [54].”
Background
Lipid-Based Nanoparticles for siRNA Delivery in Cancer Therapy: Paradigms and Challenges
Gomes-da-Silva, L. C., Fonseca, N. A., Moura, V., de Lima, M. C. P., Simões, S., & Moreira, J. N. (2012) · Accounts of Chemical Research · doi:10.1021/ar300048p · Cited by 253
Drug delivery of siRNA therapeutics: potentials and limits of nanosystems
Reischl, D., & Zimmer, A. (2008) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2008.06.001 · Cited by 256
Nanotoxicity: A Key Obstacle to Clinical Translation of siRNA-Based Nanomedicine
Xue, H. Y., Liu, S., & Wong, H. L. (2014) · Nanomedicine · doi:10.2217/nnm.13.204 · Cited by 259
Self-assembled biodegradable micellar nanoparticles of amphiphilic and cationic block copolymer for siRNA delivery
Sun, T., Du, J., Yan, L., Mao, H., & Wang, J. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.07.036 · Cited by 248
Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates
Straarup, E. M., Fisker, N., Hedtjärn, M., Lindholm, M., Rosenbohm, C., Aarup, V., Hansen, H. F., Ørum, H., Hansen, J. B., & Koch, T. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq457 · Cited by 248
Small interfering RNA for cancer treatment: overcoming hurdles in delivery
Charbe, N. B., Amnerkar, N. D., Ramesh, B., Tambuwala, M. M., Bakshi, H. A., Aljabali, A. A. A., Khadse, S. C., Satheeshkumar, R., Satija, S., Metha, M., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.10.005 · Cited by 250
“In 2006, Zimmermann et al.(77) have reported the first study of gene silencing in nonhuman primates.”
Background
Structure and Function of Cationic and Ionizable Lipids for Nucleic Acid Delivery
Sun, D., & Lu, Z. (2023) · Pharmaceutical Research · doi:10.1007/s11095-022-03460-2 · Cited by 253
Nonviral methods for siRNA delivery
Gao, K., & Huang, L. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800134q · Cited by 244
Liposome-like nanostructures for drug delivery
Gao, W., Hu, C. J., Fang, R. H., & Zhang, L. (2013) · Journal of Materials Chemistry B · doi:10.1039/c3tb21238f · Cited by 246
Antitumor Activity and Prolonged Survival by Carbon‐Nanotube‐Mediated Therapeutic siRNA Silencing in a Human Lung Xenograft Model
Podesta, J. E., Al‐Jamal, K. T., Herrero, M. A., Tian, B., Ali‐Boucetta, H., Hegde, V., Bianco, A., Prato, M., & Kostarelos, K. (2009) · Small · doi:10.1002/smll.200801572 · Cited by 249
lncRNA/MicroRNA interactions in the vasculature
Ballantyne, M. D., McDonald, R., & Baker, A. H. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.355 · Cited by 242
“technology has now been tested in several mammals including man.(63,64) Current clinical trials are investigating the safety and efficacy of RNAi-mediated therapeutics and it could be relatively easily adapted to allow RNAi therapies targeting lncRNA.”
Background
Identification and application of exogenous dsRNA confers plant protection against Sclerotinia sclerotiorum and Botrytis cinerea
Mcloughlin, A. G., Wytinck, N., Walker, P. L., Girard, I. J., Rashid, K. Y., de Kievit, T. R., Fernando, W. G. D., Whyard, S., & Belmonte, M. F. (2018) · Scientific Reports · doi:10.1038/s41598-018-25434-4 · Cited by 262
Chitosans for delivery of nucleic acids
Buschmann, M. D., Merzouki, A., Lavertu, M., Thibault, M., Jean, M., & Darras, V. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.005 · Cited by 254
“Intravenous injection of stable NA-lipid particles (SNALP) has successfully targeted the liver to silence the apolipoprotein B (ApoB) gene in mice and nonhuman primates [386].”
Induction of Bleb Structures in Lipid Nanoparticle Formulations of mRNA Leads to Improved Transfection Potency
Cheng, M. H. Y., Leung, J., Zhang, Y., Strong, C., Basha, G., Momeni, A., Chen, Y., Jan, E., Abdolahzadeh, A., Wang, X., et al. (2023) · Advanced Materials · doi:10.1002/adma.202303370 · Cited by 243
Light-Scattering Detection below the Level of Single Fluorescent Molecules for High-Resolution Characterization of Functional Nanoparticles
Zhu, S., Ma, L., Wang, S., Chen, C., Zhang, W., Yang, L., Hang, W., Nolan, J. P., Wu, L., & Yan, X. (2014) · ACS Nano · doi:10.1021/nn505162u · Cited by 235
“Lipid nanoparticles (LNPs) encapsulating siRNA are currently themost extensively clinically validated means of enabling RNA interference.(40) 42 However, it is challenging to determine the precise particle count and the fraction of loaded particles.”
Background
Small interfering RNAs (siRNAs) in cancer therapy: a nano-based approach
Mahmoodi Chalbatani, G., Dana, H., Gharagouzloo, E., Grijalvo, S., Eritja, R., Logsdon, C. D., Memari, F., Miri, S. R., Rezvani Rad, M., & Marmari, V. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200253 · Cited by 221
“97 Optimized formulations based on modifying SNALPs chemically increased their siRNA ef ﬁ cacy in vivo by reducing doses until 0.01 mg·Kg − 1 when targeted a hepatic endogenous gene.”
Influential
The synergistic effect of hierarchical assemblies of siRNA and chemotherapeutic drugs co-delivered into hepatic cancer cells
Cao, N., Cheng, D., Zou, S., Ai, H., Gao, J., & Shuai, X. (2010) · Biomaterials · doi:10.1016/j.biomaterials.2010.11.061 · Cited by 231
“Despite the great potential, an efficient delivery is essential for the applications of the small RNA interfering technique [4].”
Background
Delivery Vehicles for Small Interfering RNA In Vivo
de Fougerolles, A. R. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.928 · Cited by 232
Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting
de Paula, D., Bentley, M. V. L. B., & Mahato, R. I. (2007) · RNA · doi:10.1261/rna.459807 · Cited by 232
mRNA transcript therapy
Weissman, D. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.973859 · Cited by 228
“Reprogramming of cells DCs: HIV antigens [141-143] Infectious disease vaccines DCs: pancreatic adenocarcinoma [122,123], prostate cancer [124,125], melanoma [126-130], colon cancer [131] renal cell carcinoma [12], melanoma [14] T cells: CAR-Her-2/neo [117], CAR-mesothelin [118,119], CAR-CD19 [120,121] DCs: MUC1[114],…”
BackgroundMethod
Toxicogenomics of non-viral drug delivery systems for RNAi: Potential impact on siRNA-mediated gene silencing activity and specificity
Akhtar, S., & Benter, I. F. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.010 · Cited by 222
A Novel Mechanism Is Involved in Cationic Lipid-Mediated Functional siRNA Delivery
Lu, J. J.-Q., Langer, R., & Chen, J. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900023v · Cited by 222
Nanomedicine based approaches for the delivery of siRNA in cancer
Özpolat, B., Sood, A. K., & Lopez‐Berestein, G. (2009) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2009.02191.x · Cited by 221
Progress Toward In Vivo Use of siRNAs-II
Rettig, G. R., & Behlke, M. A. (2011) · Molecular Therapy · doi:10.1038/mt.2011.263 · Cited by 217
Pulmonary delivery of therapeutic siRNA
Lam, J. K. W., Liang, W., & Chan, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.02.006 · Cited by 223
“The SNALP demonstrated efficient in vivo gene silencing when administered intravenously in nonhuman primates [145,146].”
Background
Exploiting Endocytosis for NanomedicinesPreprint
Akinc, A., & Battaglia, G. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016980 · Cited by 215
“These LNPs all contain ionizable lipids that are positively charged under acidic conditions and are uncharged under neutral physiological conditions (Zimmermann et al. 2006; Semple et al. 2010).”
Background
RNA interference in the era of nucleic acid therapeutics
Jadhav, V., Vaishnaw, A. K., Fitzgerald, K. J., & Maier, M. A. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-02105-y · Cited by 232
“N -[(methoxypoly(ethylene glycol)2000)carbamoyl]-1,2-dimyristyloxy-propylamine (PEG-C-DMA), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and cholesterol 28 .”
Delivery of RNA interference therapeutics using polycation-based nanoparticles
Howard, K. A. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.001 · Cited by 210
Exploring Chemical Modifications for siRNA Therapeutics: A Structural and Functional Outlook
Shukla, S., Sumaria, C. S., & Pradeepkumar, P. I. (2009) · ChemMedChem · doi:10.1002/cmdc.200900444 · Cited by 212
Evaluation of Efficacy, Biodistribution, and Inflammation for a Potent siRNA Nanoparticle: Effect of Dexamethasone Co-treatment
Abrams, M. T., Koser, M. L., Seitzer, J., Williams, S. C., DiPietro, M. A., Wang, W., Shaw, A. W., Mao, X., Jadhav, V., Davide, J. P., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2009.208 · Cited by 209
CLINICAL TRIALS AND TRANSLATIONAL MEDICINE COMMENTARY: Drug Delivery Trends in Clinical Trials and Translational Medicine: Challenges and Opportunities in the Delivery of Nucleic Acid-Based Therapeutics
Xu, L., & Anchordoquy, T. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22243 · Cited by 209
Liposome based systems for systemic siRNA delivery: Stability in blood sets the requirements for optimal carrier design
Buyens, K., Smedt, S. C. D., Braeckmans, K., Demeester, J., Peeters, L., van Grunsven, L. A., du Jeu, X. D. M., Sawant, R. R., Torchilin, V. P., Farkasova, K., et al. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.009 · Cited by 207
Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy
Xu, X., Wu, J., Liu, Y., Saw, P. E., Tao, W., Yu, M., Zope, H. R., Si, M., Victorious, A. P., Rasmussen, J., et al. (2017) · ACS Nano · doi:10.1021/acsnano.6b07195 · Cited by 207
In vivo RNAi: Today and TomorrowPreprint
Perrimon, N., Ni, J.-Q., & Perkins, L. A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a003640 · Cited by 212
“Delivery is currently considered the biggest hurdle as the introduction of siRNAs systemically into body fluids can result in their degradation, off-target effects, and immune detection and subsequent reactions (see for example Zimmermann et al. 2006).”
Background
An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe−/− mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia
Schmidt, P. J., Toudjarska, I., Sendamarai, A. K., Racie, T., Milstein, S., Bettencourt, B. R., Hettinger, J., Bumcrot, D., & Fleming, M. D. (2013) · Blood · doi:10.1182/blood-2012-09-453977 · Cited by 204
Lipid-Based Nanocarriers for RNA Delivery
Xue, H. Y., Guo, P., Wen, W., & Wong, H. (2015) · Current Pharmaceutical Design · doi:10.2174/1381612821666150531164540 · Cited by 212
Structure of lipid nanoparticles containing siRNA or mRNA by dynamic nuclear polarization-enhanced NMR spectroscopy
Viger-Gravel, J., Schantz, A., Pinon, A. C., Rossini, A. J., Schantz, S., & Emsley, L. (2018) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.7b10795 · Cited by 202
Octaarginine-modified multifunctional envelope-type nano device for siRNA
Nakamura, Y., Kogure, K., Futaki, S., & Harashima, H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.03.010 · Cited by 202
An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria
Liebow, A., Li, X., Racie, T., Hettinger, J. L., Bettencourt, B. R., Najafian, N., Haslett, P. A. J., Fitzgerald, K. J., Holmes, R. P., Erbe, D. V., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030338 · Cited by 201
Next-Generation Lipids in RNA Interference Therapeutics
Rietwyk, S., & Peer, D. (2017) · ACS Nano · doi:10.1021/acsnano.7b04734 · Cited by 199
Imaging small molecule-induced endosomal escape of siRNA
Rietz, H. D., Hedlund, H., Wilhelmson, S., Nordenfelt, P., & Wittrup, A. (2020) · Nature Communications · doi:10.1038/s41467-020-15300-1 · Cited by 209
Knocking down Disease with siRNAs
Dykxhoorn, D. M., & Lieberman, J. (2006) · Cell · doi:10.1016/j.cell.2006.07.007 · Cited by 201
Nanoparticle-Mediated Drug Delivery for the Treatment of Cardiovascular Diseases
Pala, R., Anju, V. T., Dyavaiah, M., Busi, S., & Nauli, S. M. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s250872 · Cited by 213
Uptake of Extracellular Double-Stranded RNA by SID-2
McEwan, D. L., Weisman, A. S., & Hunter, C. P. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.07.014 · Cited by 195
“…ligands such as cholesterol and cell-type specific antibodies mediate an initial SID-2-like step that is capable of transporting siRNAs, this model additionally clarifies why fusing therapeutic siRNAs to these ligands increases their cellular uptake (Wolfrum et al., 2007; Zimmermann et al., 2006).”
Therapeutic potential for microRNAs
Esau, C., & Monia, B. P. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.03.007 · Cited by 198
Safety Evaluation of Lipid Nanoparticle–Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey
Sedic, M., Senn, J. J., Lynn, A., Laska, M., Smith, M., Platz, S. J., Bolen, J., Hoge, S., Bulychev, A., Jacquinet, E., et al. (2018) · Veterinary Pathology · doi:10.1177/0300985817738095 · Cited by 195
“The mRNA-loaded LNPs were generated via stepwise ethanol dilution, with an approach adapted from previously demonstrated methods.(13,30) The LNP formulation was prepared by dissolving the lipids (6Z,9Z,28Z,31Z)-heptatriaconta6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (MC3), 2 Veterinary Pathology XX(X)”
Method
Lipid nanoparticle delivery systems for siRNA-based therapeutics
Wan, C. P. L., Allen, T. M., & Cullis, P. R. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0161-z · Cited by 198
“Second, siRNAmolecules are not stable in serum and are prone to nuclease degradation [15]; the halflife for unmodified/unprotected siRNAs in serum ranges from minutes to an hour [6, 16, 17].”
Background
Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth
Crombez, L., Morris, M. C., Dufort, S., Aldrian, G., Nguyen, Q., Master, G. M., Coll, J., Heitz, F., & Divita, G. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp451 · Cited by 198
“Several reports using polycationic formulations (35), protamine-antibodies (36,37) and peptides (12,17) have largely proven that non-covalent strategies are very suitable approaches for siRNA delivery, as they improve the stability of siRNA in biological fluids, thereby increasing their overall potency.”
Background
Lipid-based nanoparticle formulations for small molecules and RNA drugs
Ickenstein, L. M., & Garidel, P. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1669558 · Cited by 193
“These lipids have been optimized to achieve maximum endosomal release and thus maximum efficacy with remarkable success [176].”
Background
Rac1 activates non-oxidative pentose phosphate pathway to induce chemoresistance of breast cancer
Li, Q., Qin, T., Bi, Z., Hong, H., Ding, L., Chen, J., Wu, W., Lin, X., Fu, W., Zheng, F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15308-7 · Cited by 194
Recent Developments in Nanoparticle-Based siRNA Delivery for Cancer Therapy
Lee, J.-M., Yoon, T., & Cho, Y. (2013) · BioMed Research International · doi:10.1155/2013/782041 · Cited by 196
MiRNA-21 silencing mediated by tumor-targeted nanoparticles combined with sunitinib: A new multimodal gene therapy approach for glioblastoma
Costa, P. M., Cardoso, A. L., Custódia, C., Cunha, P. P., de Almeida, L. P., & de Lima, M. C. P. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.002 · Cited by 189

Authors: Zimmermann, T. S., Lee, A. C. H., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M. N., Harborth, J., Heyes, J. A., Jeffs, L. B., John, M., Judge, A. D., Lam, K., McClintock, K., Nechev, L. V., Palmer, L. R., Racie, T., Röhl, I., Seiffert, S., Shanmugam, S., Sood, V., Soutschek, J., Toudjarska, I., Wheat, A. J., Yaworski, E., Zedalis, W., Koteliansky, V., Manoharan, M., Vornlocher, H.-P., & MacLachlan, I.
Affiliations: Alnylam Pharmaceuticals (United States) (US)
Electronic Arts (Canada) (CA)
Corresponding author: Zimmermann, Tracy S.
MacLachlan, Ian
ORCID: Lee, Amy C. H.
Fedoruk, Matthew N.
Harborth, Jens
Heyes, James A.
Lam, Kieu
McClintock, Kevin
Palmer, Lorne R.
Manoharan, Muthiah
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2006-03-26
Volume: 441
Issue: 7089
Pages: 111-114
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature04688
OpenAlex: W2095151181
Cited by: 1,357
References: 20
Citations by year: 2026: 21 · 2025: 22 · 2024: 30 · 2023: 42 · 2022: 40 · 2021: 35 · 2020: 35 · 2019: 46 · 2018: 30 · 2017: 47 · 2016: 54 · 2015: 70 · 2014: 97 · 2013: 113 · 2012: 111
FWCI: 46.06
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Alnylam Pharmaceuticals
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
Keywords: RNA interference, gene silencing, siRNA, apolipoprotein B, siRNA therapeutics, systemic siRNA delivery, Macaca fascicularis, non-human primates, hypercholesterolemia, LDL cholesterol, B-cell lymphoma, CARD11
MeSH terms: Animals, Apolipoproteins B, Phenotype, Primates, RNA, Messenger, RNA Interference, RNA, Small Interfering

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

RNAi-mediated gene silencing in non-human primates

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks